Revolka offers the proprietary _ai_ Protein® platform that combines machine‑learning predictions with directed‑evolution lab data to design high‑functionality proteins—such as antibodies, enzymes, and peptides—in days instead of years. Clients can use the rapid “same‑day” AI antibody design service (RevoAb®) or engage in a full design‑to‑validation partnership, reducing experimental workload, accelerating discovery, and lowering R&D costs across pharma, biotech, and industrial sectors.
Funding
$374.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Protein engineering traditionally requires extensive trial‑and‑error experiments, large datasets, and long development timelines, leading to high R&D costs and delayed therapeutic or industrial product delivery.
Solution
RevolKa provides the proprietary _ai_ Protein® platform, which fuses machine‑learning‑driven predictions with directed‑evolution laboratory data to explore the vast protein sequence space efficiently. By creating custom, low‑N AI models for each target, the platform can generate high‑functionality protein sequences—from antibodies to enzymes—in days rather than years. The company offers both a rapid “same‑day” AI antibody design service (RevoAb®) and a full‑cycle design‑to‑validation partnership, enabling clients to accelerate discovery, reduce experimental workload, and lower overall development costs.
Target Audience
Pharmaceutical and biotechnology companies, as well as research institutions and industrial firms that require accelerated protein engineering for therapeutics, enzymes, diagnostics, or other bio‑based products.
Features
- Custom AI models built on limited experimental data (Low‑N learning) for any protein class
- Integrated workflow that combines AI predictions with real‑world lab measurements to refine designs iteratively
- Rapid sequence generation with options for “instant” antibody design (up to three candidate sequences delivered same day)
- End‑to‑end service covering design, in‑silico validation, and experimental verification for antibodies, enzymes, peptides, and other biologics
- Scalable cloud‑based platform supporting high‑throughput design projects and secure data handling
- Proven acceleration record (e.g., replicating 30‑year research in 7 days) and broad applicability across pharma, biotech, chemicals, food, and environmental sectors